Studies published in JAMA and JAMA Internal Medicine highlight the benefits and risks of treating men for low testosterone.
Researchers have pinpointed harmonized references ranges for total testosterone levels in men.
Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within 6 months and declining thereafter.
Men treated with implantable testosterone pellets have a statistically significant increase in mean hematocrit, but it is unlikely to be clinically relevant.
Once-daily testosterone solution 2% (T-sol) is safe and improves sex drive and energy in men with androgen deficiency.
Once-daily 2% testosterone solution (T-sol) is safe and effective for sex drive and energy in hypogonadal men.
Men using testosterone gel experienced improvements in sex drive, sexual activity, and erectile function.
Results showed a decreased prevalence of anemia and components of metabolic syndrome after 54 weeks of treatment.
Both low testosterone and sarcopenia tied to increased mortality, with low testosterone being a better predictor.
Daily topical testosterone restored normal testosterone levels in hypogonadal men
Sexual function and mood and depressive symptoms were improved in older men who received testosterone therapy.
Selective estrogen receptor modulators may offer a viable treatment option for men with secondary hypogonadism.
Researchers found an increased odds of low testosterone with exposure as well as an increased odds with increasing age and comorbidities.
Acerus announced that its agreement with an affiliate of Endo International plc regarding the commercialization of Natesto (testosterone) nasal gel in the U.S. and Mexico will be terminated as of June 30, 2016.
Eating more protein may lower testosterone levels in women.
American Association of Clinical Endocrinologists issues position statement on CV risks of testosterone therapy.
Experts suggest that more studies are necessary to evaluate testosterone therapy in men with age-related hypogonadism.
Researchers observed no impact on rate of change of intima-media thickness, coronary artery calcium score.
Prostate cancer is more likely to be found in men with low testosterone vs. those with normal levels.
Quality studies are still needed to answer crucial questions about TRT and prostate cancer, cardiovascular risk.
These findings are based on data from more than 30,000 American men aged 40 years and older.
Undergoing testosterone replacement therapy didn't improve ejaculatory dysfunction in men with testosterone deficiency.
More than half have depression or depressive symptoms, and 25% are taking antidepressants.
Findings in older men with high cholesterol and low testosterone.
The benefits of testosterone therapy outweigh the risks, according to experts, and the FDA may need to rethink its stance.
High levels of free testosterone and bioavailable testosterone, and low levels of sex hormone-binding globulin, are tied to a decreased risk for erectile dysfunction.
New data from two studies indicate that testosterone therapy is not associated with cardiovascular risks, which challenges recent FDA decisions.
Three doses of testosterone nasal gel may help normalize testosterone levels in men with hypogonadism.
Low-dose letrozole may help treat infertility in men with obesity-related hypogonadotropic hypogonadism.
The agency now requires prescription testosterone product labels to clarify the approved use of these medications and information on potential increased risks for heart attacks and stroke.
Devices include remote heartbeat monitor, fitness smart socks and devices for monitoring glucose.
In older men, testosterone levels directly linked to sexual activity, desire.
Increases in total testosterone levels, testosterone secretion index values in middle-aged men.
Low serum testosterone appears to be linked to adverse outcomes in men with type 2 diabetes.
Long-term testosterone therapy did not increase incidence of prostate cancer in hypogonadal men.
Testosterone testing appears to be increasing, especially among men with comorbidities associated with hypogonadism.
The presence of axillary hair or use of deoderant or antiperspirant did not affect the absorption of a testosterone solution.
Hypogonadism is disproportionately high in men with spinal cord injury, leading researchers to suggest a connection between the two conditions.
Older men with lower baseline testosterone experience greater increases in prostate-specific antigen with testosterone gel use.
Low testosterone may increase cardiovascular risk in middle-aged men with type 2 diabetes.
In rats, testosterone appeared to raise the risk for prostate tumor growth.
A new Endocrine Society clinical practice guideline advises against the use of testosterone in healthy women.
Lipocine announced top-line results from its Phase 3 SOAR clinical trial evaluating the efficacy and safety of LPCN 1021, an oral testosterone agent in hypogonadal men with low testosterone.
FDA panel votes 20-1 to tighten use of testosterone replacement therapy.
Expert panel to decide whether the prescribing information on testosterone drugs should be changed.
Chemicals found in many household products may reduce androgen levels in both sexes.
Upsher-Smith announced the launch of Testosterone Gel 1%, the generic version of Vogelxo gel, in 3 different configurations.
The FDA now requires a general warning in the drug labeling of all approved testosterone products regarding the risk of venous blood clots.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Cochrane Data Release and the Case for "Open Science"
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Characteristics of Acquired Partial Lipodystrophy With Metabolic Abnormalities
- Poor Glycemic Control Associated With Higher Risk for Dementia in Older Adults With T1D
- Shift Seen From EDs to Urgent Care for Low-Acuity, Acute Care